Dolutegravir And Lamivudine Tablets

Description

Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains dolutegravir, an integrase inhibitor, and lamivudine, a reverse-transcriptase inhibitor. It is taken by mouth. Dolutegravir is an integrase inhibitor, while lamivudine is a nucleoside reverse-transcriptase inhibitor. It was approved for use in the United States in April 2019, and in the European Union in July 2019. The most common side effects are headache, diarrhoea, nausea (feeling sick) and difficulty sleeping. The most common serious side effects are allergic reactions, including rash and severe liver problems